PAYER ANALYSIS: ‘CADILLAC TAX’ ON HIGH-COST HEALTH PLANS COULD AFFECT 1 IN 5 EMPLOYERS IN 2022
[/infobox] A new KFF analysis estimates that the Affordable Care Act’s tax on high-cost health plans would affect one in five (21 percent) employers offering health benefits when it takes effect in 2022 unless employers change their health plans. An even larger share (31 percent) could be affected when workers’ voluntary
ANGIODYNAMICS SELLS NAMIC fluid management portfolio
AngioDynamics Inc., a provider of innovative, minimally invasive medical devices for oncology, vascular access and peripheral vascular disease, has agreed to sell its NAMIC fluid management portfolio to Medline Industries Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The
CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES
Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross
ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT
As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock. Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe
VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease
The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.
VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System
By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”
MERZ REGAINS SOLE DISTRIBUTION OF ASCLERA FROM ANGIODYNAMICS
Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins. Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All HCPs will now be able to purchase Asclera directly
SOCIAL SECURITY ERROR JEOPARDIZES MEDICARE COVERAGE FOR 250,000 SENIORS
By Susan Jaffe At least a quarter of a million Medicare beneficiaries may receive bills for as many as five months of premiums they thought they already paid. But they shouldn’t toss the letter in the garbage. It’s not a scam or a mistake. Because of what the
A LARGE EMPLOYER ‘FRAMES’ THE ‘MEDICARE FOR ALL’ DEBATE
By Phil Galewitz Walk into a big-box retailer such as Walmart or Michaels and you’re likely to see MCS Industries’ picture frames, decorative mirrors or kitschy wall décor. Adjacent to a dairy farm a few miles west of downtown Easton, MCS is the nation’s largest maker of such household
CVS still defending the Aetna merger deal
CVS Health is making the case for its merger with Aetna to two very different audiences beginning June 3. CVS held its annual investor day and issued a long-term strategic plan to “accelerate growth” ahead of the day’s proceedings, aimed at nervous investors concerned about its recent financial performance post-merger. CVS warned that it